OBJECTIVE: We examined the effects of antiretroviral regimens on blood pressure (BP). METHOD: This retrospective study examined systolic and diastolic BP (SBP and DBP) measurements among participants of a State of Hawaii Department of Health program from January 1995 to July 2001. The change in BP during four consecutive 6-month visits was estimated using linear regression and was interpreted as the change in BP per year. BP changes among the antiretroviral treatment groups were compared to untreated controls. RESULTS: Of 1,601 patients identified, 286 met the criteria for inclusion. After adjustment for baseline age, BP, and CD4+ count, there was an increase in SBP by 4.71 mmHg/year (p =.005) and DBP by 2.26 mmHg/year (p =.076) among patients initiating HAART. Among these patients, an increase of 4.75 mmHg/year in SBP (p =.002) and 1.96 mmHg/year in DBP (p =.042) was seen with HAART regimens containing a protease inhibitor (PI) but no nonnucleoside reverse transcriptase inhibitor (NNRTI). In NNRTI-containing HAART regimens without PIs, an increase of 3.21 mmHg/year in SBP (p =.011) and 2.62 mmHg/year in DBP (p =.050) was observed. No significant BP changes were noted with patients on regimens containing only nucleoside reverse transcriptase inhibitors (NRTIs). CONCLUSION: The use of NNRTI- or PI-containing HAART is associated with elevation of both SBP and DBP in HIV-infected individuals.
OBJECTIVE: We examined the effects of antiretroviral regimens on blood pressure (BP). METHOD: This retrospective study examined systolic and diastolic BP (SBP and DBP) measurements among participants of a State of Hawaii Department of Health program from January 1995 to July 2001. The change in BP during four consecutive 6-month visits was estimated using linear regression and was interpreted as the change in BP per year. BP changes among the antiretroviral treatment groups were compared to untreated controls. RESULTS: Of 1,601 patients identified, 286 met the criteria for inclusion. After adjustment for baseline age, BP, and CD4+ count, there was an increase in SBP by 4.71 mmHg/year (p =.005) and DBP by 2.26 mmHg/year (p =.076) among patients initiating HAART. Among these patients, an increase of 4.75 mmHg/year in SBP (p =.002) and 1.96 mmHg/year in DBP (p =.042) was seen with HAART regimens containing a protease inhibitor (PI) but no nonnucleoside reverse transcriptase inhibitor (NNRTI). In NNRTI-containing HAART regimens without PIs, an increase of 3.21 mmHg/year in SBP (p =.011) and 2.62 mmHg/year in DBP (p =.050) was observed. No significant BP changes were noted with patients on regimens containing only nucleoside reverse transcriptase inhibitors (NRTIs). CONCLUSION: The use of NNRTI- or PI-containing HAART is associated with elevation of both SBP and DBP in HIV-infected individuals.
Authors: Roger C McIntosh; Michael Antoni; Adam Carrico; Ron Duran; Barry E Hurwitz; Gail Ironson; Mary Ann Fletcher; Nancy Klimas; Mahendra Kumar; Neil Schneiderman Journal: J Behav Med Date: 2017-02-02
Authors: Victor Valcour; Priscilla Yee; Andrew E Williams; Bruce Shiramizu; Michael Watters; Ola Selnes; Robert Paul; Cecilia Shikuma; Ned Sacktor Journal: J Neurovirol Date: 2006-10 Impact factor: 2.643
Authors: Victor G Valcour; Cecilia M Shikuma; Bruce T Shiramizu; Andrew E Williams; Michael R Watters; Pamela W Poff; John S Grove; Ola A Selnes; Ned C Sacktor Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: Priscilla Y Hsue; Peter W Hunt; Jennifer E Ho; Husam H Farah; Amanda Schnell; Rebecca Hoh; Jeffrey N Martin; Steven G Deeks; Ann F Bolger Journal: Circ Heart Fail Date: 2009-11-20 Impact factor: 8.790
Authors: Matthew C Foy; Michelle M Estrella; Gregory M Lucas; Faryal Tahir; Derek M Fine; Richard D Moore; Mohamed G Atta Journal: Clin J Am Soc Nephrol Date: 2013-05-16 Impact factor: 8.237